What is 2nd line chemotherapy?

Second-line therapy is administered for disease progression, recurrence, or intolerable adverse effects following administration of initial chemotherapy. We defined a second-line chemotherapy agent in 1 of 2 ways.

What chemo is used for cholangiocarcinoma?

The standard chemotherapy drugs for bile duct cancer are gemcitabine (Gemzar®) and cisplatin. Other drugs sometimes used include fluorouracil (also called 5-FU), oxaliplatin (Eloxatin®), and capecitabine (Xeloda®).

How many cycles of chemo does it take for cholangiocarcinoma?

Treatment Regimens The 2 most common regimens used were gemcitabine/cisplatin (62%) and capecitabine/oxaliplatin (16%). Patients received a median 6 cycles of first-line chemotherapy (range 2–28 cycles).

Does Chemo work for cholangiocarcinoma?

Chemo might shrink the tumor enough to improve the odds that surgery will be successful. This is called neoadjuvant treatment. As part of the liver transplant process: Chemo may be used to keep bile duct cancer under control while waiting for a liver transplant.

Which is the second line treatment for cholangiocarcinoma?

Chemotherapy is the most common second-line treatment in patients with cholangiocarcinoma. FGFR2 fusions occur in 13-17% of cholangiocarcinoma and several targeted tyrosine kinase inhibitors are in development for this patient population.

Which is the most common second line cancer?

The study team reported that cholangiocarcinoma is the most common biliary tract cancer with an estimated incidence of 1.67/100,000 in the US and 0.45‒3.36/100,000 in Europe. Chemotherapy is the most common second-line treatment in patients with cholangiocarcinoma.

Which is the second line chemotherapy for gastrointestinal cancer?

Abstract SO-5. Javle M, Sadeghi S, Roychowdhury S, et al. Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis. ESMO World Congress on Gastrointestinal Cancer 2020 Virtual (1-4 July).

How often to take infigratinib for cholangiocarcinoma?

Patients with advanced cholangiocarcinoma and FGFR2 fusions after prior treatment with gemcitabine-based chemotherapy were enrolled in a single-arm phase II study (NCT02150967) and received infigratinib (previously know as BGJ398) 125 mg orally once daily on days 1-21.